KR20010006344A - 자궁내막암의 검출 방법 - Google Patents
자궁내막암의 검출 방법 Download PDFInfo
- Publication number
- KR20010006344A KR20010006344A KR1019997009429A KR19997009429A KR20010006344A KR 20010006344 A KR20010006344 A KR 20010006344A KR 1019997009429 A KR1019997009429 A KR 1019997009429A KR 19997009429 A KR19997009429 A KR 19997009429A KR 20010006344 A KR20010006344 A KR 20010006344A
- Authority
- KR
- South Korea
- Prior art keywords
- mmp
- uterine
- endometrial cancer
- measured
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 59
- 206010014733 Endometrial cancer Diseases 0.000 title claims abstract description 56
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims abstract description 56
- 238000001514 detection method Methods 0.000 title description 14
- 239000012530 fluid Substances 0.000 claims abstract description 32
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims abstract 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims description 75
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 36
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 28
- 102000004190 Enzymes Human genes 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 23
- 238000002965 ELISA Methods 0.000 claims description 17
- 102000013382 Gelatinases Human genes 0.000 claims description 14
- 108010026132 Gelatinases Proteins 0.000 claims description 14
- 230000002357 endometrial effect Effects 0.000 claims description 13
- 210000005168 endometrial cell Anatomy 0.000 claims description 12
- 238000005259 measurement Methods 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 229920002866 paraformaldehyde Polymers 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 210000004696 endometrium Anatomy 0.000 claims description 5
- 239000000834 fixative Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 4
- 238000000326 densiometry Methods 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 238000003271 compound fluorescence assay Methods 0.000 claims description 3
- 210000000981 epithelium Anatomy 0.000 claims description 3
- 238000003127 radioimmunoassay Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 3
- 238000003149 assay kit Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 abstract description 6
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 abstract 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 abstract 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 28
- 201000011510 cancer Diseases 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 24
- 239000000499 gel Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000008273 gelatin Substances 0.000 description 9
- 229920000159 gelatin Polymers 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 206010046766 uterine cancer Diseases 0.000 description 9
- 108010010803 Gelatin Proteins 0.000 description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 description 8
- 235000019322 gelatine Nutrition 0.000 description 8
- 235000011852 gelatine desserts Nutrition 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000009802 hysterectomy Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102100030417 Matrilysin Human genes 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004791 biological behavior Effects 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002632 myometrial effect Effects 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014728 Endometrial adenoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 238000009649 Feulgen staining Methods 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- UJTABUXRHHQREO-UHFFFAOYSA-N acetic acid;amino(phenyl)mercury Chemical compound CC(O)=O.N[Hg]C1=CC=CC=C1 UJTABUXRHHQREO-UHFFFAOYSA-N 0.000 description 1
- 230000003322 aneuploid effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 108010071626 caseinase Proteins 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003370 dye binding method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO5736A AUPO573697A0 (en) | 1997-03-20 | 1997-03-20 | Diagnosis of endometrial cancer |
| AUPO5736 | 1997-03-20 | ||
| PCT/AU1998/000189 WO1998042865A1 (en) | 1997-03-20 | 1998-03-20 | Detection of endometrial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010006344A true KR20010006344A (ko) | 2001-01-26 |
Family
ID=3800039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019997009429A Withdrawn KR20010006344A (ko) | 1997-03-20 | 1998-03-20 | 자궁내막암의 검출 방법 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6607894B1 (enExample) |
| EP (1) | EP0979304B1 (enExample) |
| JP (2) | JP4183757B2 (enExample) |
| KR (1) | KR20010006344A (enExample) |
| CN (1) | CN1257550A (enExample) |
| AT (1) | ATE331039T1 (enExample) |
| AU (1) | AUPO573697A0 (enExample) |
| CA (1) | CA2284099C (enExample) |
| DE (1) | DE69835010T2 (enExample) |
| ES (1) | ES2268767T3 (enExample) |
| MY (1) | MY119567A (enExample) |
| NZ (1) | NZ337868A (enExample) |
| WO (1) | WO1998042865A1 (enExample) |
| ZA (1) | ZA982403B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2322023A1 (en) * | 1998-03-05 | 1999-09-10 | John D. Burczak | A novel method of detecting and monitoring endometrial and uterine cancers |
| AUPQ219799A0 (en) | 1999-08-13 | 1999-09-02 | R. Lurie Pty Ltd | Apparatus for obtaining potological samples |
| US7094754B2 (en) | 2001-08-16 | 2006-08-22 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US6906036B2 (en) | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| US7071164B2 (en) | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
| US7186693B2 (en) | 2001-08-16 | 2007-03-06 | Kimberly - Clark Worldwide, Inc. | Metalloproteinase inhibitors for wound healing |
| DE10217677A1 (de) | 2002-04-19 | 2003-11-06 | Bayer Ag | Verwendung von Aufhellern zur Herstellung von Streichmassen |
| US7148194B2 (en) | 2002-12-30 | 2006-12-12 | Kimberly-Clark Worldwide, Inc. | Method to increase fibronectin |
| US7189700B2 (en) | 2003-06-20 | 2007-03-13 | Kimberly-Clark Worldwide, Inc. | Anti-chrondrosarcoma compounds |
| US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20050112622A1 (en) * | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| ATE463743T1 (de) * | 2004-07-23 | 2010-04-15 | Ct De Rech Public De La Sante | Überwachung von herzversagen |
| US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
| US20060177448A1 (en) * | 2005-02-09 | 2006-08-10 | Genentech, Inc. | Inhibiting HER2 shedding with matrix metalloprotease antagonists |
| WO2007086915A2 (en) * | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| RU2304782C1 (ru) * | 2005-12-28 | 2007-08-20 | Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова | Способ прогнозирования рецидива эндометриоидной кисты яичника |
| US8592393B2 (en) | 2007-11-02 | 2013-11-26 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009059284A2 (en) | 2007-11-02 | 2009-05-07 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| US20120183976A1 (en) * | 2009-04-16 | 2012-07-19 | He Zhou | Methods of assessing activity of a polysaccharide composition |
| DK2456889T3 (en) | 2009-07-24 | 2014-12-01 | Geadic Biotec Aie | Markers of endometrial cancer |
| JP5982361B2 (ja) | 2010-04-16 | 2016-08-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | 組織標的化方法 |
| RU2430371C1 (ru) * | 2010-04-26 | 2011-09-27 | Учреждение Российской академии наук Институт ядерной физики им. Г.И. Будкера Сибирского отделения РАН (ИЯФ СО РАН) | Способ дифференциальной диагностики и прогноза миомы и рака эндометрия |
| CA2795868A1 (en) | 2010-06-17 | 2011-12-22 | Momenta Pharmaceuticals, Inc. | Methods and compositions for modulating hair growth |
| AU2012261953A1 (en) * | 2011-06-03 | 2013-12-12 | University Of South Alabama | Methods and compositions for detecting endometrial or ovarian cancer |
| WO2013044187A2 (en) * | 2011-09-22 | 2013-03-28 | Memorial Sloan-Kettering Cancer Center | Detecting ovarian cancer |
| PL2809801T3 (pl) * | 2012-01-31 | 2018-12-31 | SPEISER, Paul | Nieinwazyjna diagnoza raka |
| US10016449B2 (en) | 2013-05-28 | 2018-07-10 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions |
| WO2016000028A1 (en) * | 2014-07-02 | 2016-01-07 | Bionomics Limited | Predictive biomarkers |
| WO2016127067A1 (en) * | 2015-02-06 | 2016-08-11 | Quest Diagnostics Investments Incorporated | Compositions and methods for determining endometrial cancer prognosis |
| CA3286798A1 (en) * | 2016-05-04 | 2025-10-30 | Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca | Markers of endometrial cancer |
| IN202021002695A (enExample) | 2020-01-21 | 2021-07-23 | ||
| CN112961921B (zh) * | 2021-03-26 | 2022-07-01 | 中国医学科学院北京协和医院 | 一种用于判断早期子宫内膜癌预后的制剂及复发风险模型 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5280106A (en) * | 1988-05-20 | 1994-01-18 | Liotta Lance A | Matrix metalloproteinase peptides: role in diagnosis and therapy |
| US5324634A (en) | 1992-03-31 | 1994-06-28 | The Research Foundation Of State University Of New York | Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer |
| WO1994005807A1 (en) * | 1992-08-28 | 1994-03-17 | Dickson Robert B | Matrix-degrading metalloproteinase |
| EP0674710B1 (en) * | 1992-11-16 | 2003-05-02 | Cancer Research Fund Of Contra Costa | Peptides with broad neoplastic specificity |
-
1997
- 1997-03-20 AU AUPO5736A patent/AUPO573697A0/en not_active Abandoned
-
1998
- 1998-03-20 CA CA2284099A patent/CA2284099C/en not_active Expired - Fee Related
- 1998-03-20 ZA ZA982403A patent/ZA982403B/xx unknown
- 1998-03-20 US US09/381,454 patent/US6607894B1/en not_active Expired - Fee Related
- 1998-03-20 CN CN98805312A patent/CN1257550A/zh active Pending
- 1998-03-20 KR KR1019997009429A patent/KR20010006344A/ko not_active Withdrawn
- 1998-03-20 ES ES98909221T patent/ES2268767T3/es not_active Expired - Lifetime
- 1998-03-20 JP JP54453698A patent/JP4183757B2/ja not_active Expired - Fee Related
- 1998-03-20 WO PCT/AU1998/000189 patent/WO1998042865A1/en not_active Ceased
- 1998-03-20 MY MYPI98001218A patent/MY119567A/en unknown
- 1998-03-20 AT AT98909221T patent/ATE331039T1/de not_active IP Right Cessation
- 1998-03-20 DE DE69835010T patent/DE69835010T2/de not_active Expired - Lifetime
- 1998-03-20 NZ NZ337868A patent/NZ337868A/en not_active IP Right Cessation
- 1998-03-20 EP EP98909221A patent/EP0979304B1/en not_active Expired - Lifetime
-
2007
- 2007-01-09 JP JP2007001867A patent/JP2007202556A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2284099C (en) | 2010-04-27 |
| CN1257550A (zh) | 2000-06-21 |
| EP0979304A1 (en) | 2000-02-16 |
| AUPO573697A0 (en) | 1997-04-10 |
| EP0979304A4 (en) | 2003-06-11 |
| ZA982403B (en) | 1998-10-21 |
| US6607894B1 (en) | 2003-08-19 |
| EP0979304B1 (en) | 2006-06-21 |
| ES2268767T3 (es) | 2007-03-16 |
| ATE331039T1 (de) | 2006-07-15 |
| JP2007202556A (ja) | 2007-08-16 |
| WO1998042865A1 (en) | 1998-10-01 |
| JP2002501613A (ja) | 2002-01-15 |
| DE69835010D1 (de) | 2006-08-03 |
| NZ337868A (en) | 2002-05-31 |
| DE69835010T2 (de) | 2007-06-06 |
| CA2284099A1 (en) | 1998-10-01 |
| MY119567A (en) | 2005-06-30 |
| JP4183757B2 (ja) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010006344A (ko) | 자궁내막암의 검출 방법 | |
| CN100570366C (zh) | 基于溶液的检测方法 | |
| Bianco Jr et al. | Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. | |
| US7361474B2 (en) | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer | |
| EP1025444B1 (en) | Determination of cellular growth abnormality | |
| CN112601961B (zh) | 通过尿液生物标志物的方式体外诊断前列腺癌的方法 | |
| Makris et al. | Cytological evaluation of biological prognostic markers from primary breast carcinomas | |
| US8058024B2 (en) | Devices for the detection of the presence and/or activity of proteases in biological samples | |
| JP5155309B2 (ja) | 患者の循環液中のＭＭＰ−７の測定を利用した転移した膀胱ガンを診断およびモニターするためのｉｎｖｉｔｒｏ方法 | |
| JP3483534B2 (ja) | 子宮頸異形成及び癌を検出するための生化学的方法 | |
| JP2006311860A (ja) | 組織のリモデリングに関連した状態のための非観血的酵素スクリーン | |
| WO2001096876A1 (fr) | Test immunologique et kit de diagnostic d'un adenocarcinome de la prostate | |
| AU728286B2 (en) | Detection of endometrial cancer | |
| MXPA99008616A (en) | Detection of endometrial cancer | |
| Poh et al. | Prostate-specific antigen in breast disease | |
| RU2690379C1 (ru) | Способ прогнозирования темпов роста лейомиомы матки у женщин репродуктивного возраста | |
| EP1085097B1 (en) | Method for judging effectiveness of protease inhibitors | |
| Yu Ng et al. | Measurement of serum CA-125 concentrations does not improve the value of Chlamydia trachomatis antibody in predicting tubal pathology at laparoscopy | |
| Mool et al. | Immunohistochemical expression of Estrogen and Progesterone Receptor in Endometrium of Women with Abnormal Uterine Bleeding. | |
| WO2000023613A1 (en) | A method of assessing a matter associated with parturition in a pregnant individual | |
| Purified | Improving the Clinical Utility of the Serum PSA Test |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19990920 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |